Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,509 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer.
Makrakis D, Talukder R, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Grant M, Lythgoe MP, Pinato DJ, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Di Lorenzo G, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Yu EY, Wright JL, Grivas P, Khaki AR. Makrakis D, et al. Among authors: agarwal n. BJU Int. 2022 Nov;130(5):592-603. doi: 10.1111/bju.15603. Epub 2021 Oct 25. BJU Int. 2022. PMID: 34597472 Free PMC article.
Recent advances in immunotherapy for the treatment of prostate cancer.
Sonpavde G, Agarwal N, Choueiri TK, Kantoff PW. Sonpavde G, et al. Among authors: agarwal n. Expert Opin Biol Ther. 2011 Aug;11(8):997-1009. doi: 10.1517/14712598.2011.575357. Epub 2011 Jun 15. Expert Opin Biol Ther. 2011. PMID: 21675925 Review.
Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma.
Maughan BL, Agarwal N, Hussain SA, Boucher KM, Von Der Maase H, Kaufman DS, Lorusso V, Moore MJ, Galsky MD, Sonpavde G. Maughan BL, et al. Among authors: agarwal n. Clin Genitourin Cancer. 2013 Sep;11(3):316-20. doi: 10.1016/j.clgc.2012.12.007. Epub 2013 Jan 16. Clin Genitourin Cancer. 2013. PMID: 23332638 Clinical Trial.
Metabolic complications with the use of mTOR inhibitors for cancer therapy.
Sivendran S, Agarwal N, Gartrell B, Ying J, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Galsky MD. Sivendran S, et al. Among authors: agarwal n. Cancer Treat Rev. 2014 Feb;40(1):190-6. doi: 10.1016/j.ctrv.2013.04.005. Epub 2013 May 16. Cancer Treat Rev. 2014. PMID: 23684373 Free PMC article. Review.
Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.
Pond GR, Bellmunt J, Fougeray R, Choueiri TK, Qu AQ, Niegisch G, Albers P, Di Lorenzo G, Salhi Y, Galsky MD, Agarwal N, Necchi A, Sonpavde G. Pond GR, et al. Among authors: agarwal n. Clin Genitourin Cancer. 2013 Dec;11(4):495-500. doi: 10.1016/j.clgc.2013.04.025. Epub 2013 Jun 22. Clin Genitourin Cancer. 2013. PMID: 23800847
2,509 results